Royal Postgraduate Medical School

Joe Conaghan, PhD, HCLD, Named CCRM Fertility's Director of Science and Training

Retrieved on: 
Wednesday, July 5, 2023
University, Education, Pacific Ocean, Embryology, Culture, Teaching, University of California, San Francisco, San Francisco State University, Royal Postgraduate Medical School, Research, Doctor of Philosophy, IVF, Science, Andrology, Fertility, Metabolism, Patient, UCSF, SAN, Hammersmith Hospital, Science and technology in Asia, Emil Steinberger (endocrinologist), Nursing, Birth control

SAN FRANCISCO, July 5, 2023 /PRNewswire/ -- CCRM Fertility, the global pioneer in fertility treatment, research and science, has named Joe Conaghan, PhD, HCLD, as the director of science and education. An internationally recognized embryologist, Dr. Conaghan is a board-certified high-complexity clinical laboratory director in the disciplines of embryology and andrology. In his new role at CCRM Fertility, he will be responsible for overseeing the network's West Coast lab operations; leading informative internal lab training initiatives to support embryologists' continuing education; and helping manage network research and presentations internally and for industry initiatives.

Key Points: 
  • SAN FRANCISCO, July 5, 2023 /PRNewswire/ -- CCRM Fertility , the global pioneer in fertility treatment, research and science, has named Joe Conaghan, PhD, HCLD, as the director of science and education.
  • An internationally recognized embryologist, Dr. Conaghan is a board-certified high-complexity clinical laboratory director in the disciplines of embryology and andrology.
  • "It's an honor to have a hand in elevating CCRM Fertility's cutting-edge lab operations," said Dr. Conaghan.
  • To learn more about CCRM Fertility, please visit ccrmivf.com/ .

LanguageLine Solutions Takes Home Business Excellence Award

Retrieved on: 
Friday, August 5, 2022
Defense Language Institute, MPCC, LanguageLine Solutions, Linguistics, International studies, Royal Postgraduate Medical School, Communication, Solution, Entertainment

MONTEREY, Calif., Aug. 5, 2022 /PRNewswire/ -- Highlighting a year in which the company is celebrating its 40th anniversary in Monterey, LanguageLine Solutions has won the 2022 Monterey Peninsula Chamber of Commerce Business Excellence Award. The award, which came in the "Services to Businesses" category, was announced at MPCC's annual dinner, which was widely attended by civic leaders in Monterey County.

Key Points: 
  • MONTEREY, Calif., Aug. 5, 2022 /PRNewswire/ -- Highlighting a year in which the company is celebrating its 40th anniversary in Monterey, LanguageLine Solutions has won the 2022 Monterey Peninsula Chamber of Commerce Business Excellence Award.
  • The award is the result of two rounds of voting throughout July by MPCC members and their constituents.
  • In 1982, LanguageLine Solutions was founded in Monterey.
  • "Forty years ago, LanguageLine was launched in the laundry room of a Monterey rental home," President and CEO Scott W. Klein said.

Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

Retrieved on: 
Thursday, March 31, 2022
Trustee, Therapy, Register, Research, SEC, Physiology, Medicine, CEO, Exploration, Royal Postgraduate Medical School, Technology, Rockefeller University, GLOBE, Thermo Fisher Scientific, Annual report, Chairperson, Health, Senior, National Medical Fellowships, Student, Science, Imperial College London, AVP, Pharmacy, NASDAQ, DNA, Form, Forward-looking statement, Board, Pharmacology, Proteome, Genomics, Proteoform, Board of directors, The Mother's Service Society, San Francisco Bay Area, Drug discovery, Protein, Business development, Queen Mary University of London, Biochemistry, Leadership, Clinical pharmacology, Coronavirus Scientific Advisory Board (Turkey), Associate, Mother, Doctor of Philosophy, Merck & Co., R, Proteomics, Pharmaceutical industry, Management, Nautilus, Merck, Illumina

SEATTLE, March 31, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karen Akinsanya, Ph.D., to its Board of Directors.

Key Points: 
  • SEATTLE, March 31, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karen Akinsanya, Ph.D., to its Board of Directors.
  • in biochemistry at Queen Mary University of London, and her Ph.D. in endocrine physiology from the Royal Postgraduate Medical School at Imperial College in London.
  • Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.
  • Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements.

Federation Bio Expands Leadership Team To Support Continued Advancement of Engineered Bacterial Cell Therapies

Retrieved on: 
Tuesday, November 30, 2021
Genentech, Corcept Therapeutics, Royal Postgraduate Medical School, Federation, Industry, Nephrology, Endocrinology, University of California, San Francisco, Hammersmith Hospital, Inflammation, Amgen, SAN, University, Lists of diseases, Therapy, Genetic engineering, School, Law, University Hospital Heidelberg, Roche, Biotechnology, FDA, Bio, Pharmaceutical industry, Medicine

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- Federation Bio , a biotechnology company pioneering engineered bacterial cell therapies, today announced the appointment of two new members to its executive team.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- Federation Bio , a biotechnology company pioneering engineered bacterial cell therapies, today announced the appointment of two new members to its executive team.
  • Andreas Grauer, M.D., and Jessie Richardson, J.D., Ph.D.,have joined Federation Bio as chief medical officer and general counsel, respectively.
  • "Andreas and Jessie are both recognized industry leaders whose collective expertise perfectly complements that of our existing leadership team," said Emily Drabant Conley, Ph.D., chief executive officer at Federation Bio.
  • Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies.